Growart (Levocarnitine)

Growart is indicated for conditions where carnitine levels are insufficient or where enhanced fatty‑acid oxidation is desired.

• Management of primary or secondary carnitine deficiency diagnosed by a healthcare professional.
• Adjunct support for patients with metabolic disorders that affect fatty‑acid utilization.
• Supplementation during periods of increased energy demand, such as prolonged exercise or fasting.
• Potential aid in the dietary management of certain inherited mitochondrial disorders.
• Support for individuals following a low‑carnitine diet or receiving long‑term parenteral nutrition.
• Use as part of a nutritional regimen for athletes seeking to improve endurance performance.

The safety profile of levocarnitine in oral form is generally favorable, with most users experiencing only mild, transient effects.

Common

• Mild gastrointestinal discomfort such as nausea or abdominal cramping.
• Transient headache or dizziness.
• Unusual body odor, often described as fishy, due to metabolite excretion.
• Loose stools or mild diarrhea.
• Mild metallic taste in the mouth.
• Temporary fatigue or weakness during initial dosing.

Serious

• Allergic reactions including rash, pruritus, or angioedema.
• Severe hypotension or cardiovascular instability (rare).
• Elevated serum levels of trimethylamine N‑oxide (TMAO) in susceptible individuals.
• Liver enzyme elevations in patients with pre‑existing hepatic disease.
• Rare cases of seizures reported in patients with underlying neurological disorders.

When considering Growart, certain precautions should be observed to ensure safe and appropriate use.

• Confirm a diagnosis of carnitine deficiency or related metabolic condition before initiating supplementation.
• Use under medical supervision in patients with renal or hepatic impairment.
• Pregnancy and breastfeeding status should be discussed with a healthcare provider, as safety data are limited.
• Do not exceed the recommended daily amount indicated on the product label.
• Monitor for signs of allergic reaction, especially during the first weeks of therapy.
• Individuals with a history of seizures should be evaluated before use.

Levocarnitine may interact with certain medications or substances, influencing their effectiveness or safety profile.

Avoid

• Concurrent use with valproic acid, which may reduce carnitine levels.
• High-dose trimethylamine N‑oxide (TMAO) supplements, as combined exposure can increase cardiovascular risk.
• Co-administration with certain antibiotics (e.g., carbapenems) may interfere with carnitine absorption.

Use with caution

• Anticoagulant therapy (e.g., warfarin) – monitor INR as carnitine may affect clotting parameters.
• Thyroid hormone replacement – levocarnitine can alter peripheral conversion of T4 to T3.
• Dialysis patients receiving other amino‑acid supplements – adjust dosing to avoid excess accumulation.
• Alcohol consumption – may exacerbate gastrointestinal side effects.
• Patients on anticonvulsants should be monitored, as levocarnitine may affect seizure threshold.